Systematic reviews are of great importance in the current era of evidence-based medicine. They provide transparent and reproducible insight into the available scientific evidence for a specific question and the possible lack thereof. Systematic reviews form the basis for evidence-based guidelines, which are essential for the translation of scientific evidence into clinical practice. In this way, the care and thus the health of children with cancer and survivors can be optimized.
The editorial base of Cochrane Childhood Cancer (https://childhoodcancer.cochrane.org/), of which I’m one of the Coordinating Editors, is located in the Princess Máxima Center for pediatric oncology and its main objective is to carry out and (inter) nationally support systematic reviews of the field of pediatric oncology and survivorship care. In addition to performing my own systematic reviews I provide methodological support for all Cochrane Childhood Cancer systematic reviews. Furthermore I’m involved in methodological research in the field of systematic reviews and provide education. I’m also involved in the preparation of evidence-based guidelines.
Besides systematic reviews and guidelines, I’m also involved in research into the late effects of childhood cancer treatment, especially cardiac late effects, both nationally and internationally, for example within the LATER CARD consortium and the European PanCareSurFup study.
Supervisor of: Ogechukwu Asogwa (Research Associate systematic reviews and guidelines)
Supervisor: Prof. Dr. Leontien Kremer
Mulder RL, Bresters D, Van den Hof M, Koot BG, Castellino SM, Loke YKK, Post PN, Postma A, Szőnyi LP, Levitt GA, Bardi E, Skinner R, van Dalen EC. Hepatic late adverse effects after antineoplastic treatment for childhood cancer. Cochrane Database Syst Rev. 2019;4(4):CD008205.
Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, van der Pal HJ, van Dalen EC, Kremer LCM. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. J Clin Oncol. 2018;36(21):2135-2144.
Skoetz N, Goldkuhle M, Weigl A, Dwan K, Labonté V, Dahm P, Meerpohl JJ, Djulbegovic B, van Dalen EC. Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. J Clin Epidemiol. 2019;108:1-9.
Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, Bonne NX, Brock PR, Brooks B, Carleton B, Caron E, Chang KW, Johnston K, Knight K, Nathan PC, Orgel E, Prasad PK, Rottenberg J, Scheinemann K, de Vries ACH, Walwyn T, Weiss A, Am Zehnhoff-Dinnesen A, Cohn RJ, Landier W; International Guideline Harmonization Group ototoxicity group. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019 Jan;20(1):e29-e41.
Feijen EAM, Leisenring WM, Stratton KL, Ness KK, van der Pal HJH, van Dalen EC, Armstrong GT, Aune GJ, Green DM, Hudson MM, Loonen J, Oeffinger KC, Robison LL, Yasui Y, Kremer LCM, Chow EJ. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncol. 2019;5(6):864-871.